AZ Vaccine Sales Beat Estimates - Vax Giant now turns to antibody treatment
AstraZeneca's beaten expectations recording $1.15BN sales for Q1 - largely boosted by its Covid-19 vaccine. The number eclipsed projections made by Credit Suisse, as China accounted for around 16% of sales in 2021.
Its jab was AZ's second-best selling product in 2021 too, but a dip is expected across this year. Instead, the Anglo-Swedish firm is turning attention to its antibody coronavirus treatment called Evusheld.
The vaccine developed alongside Oxford Univ. is predicted to see a massive dip in sales, due to competition, concerns about its shelf life and side effects linked to blood clots.
The drugmaker says it is confident it will maintain revenue forecasts for the coming year, despite shares falling for a number of its products.
Subscribe to RT t.me/rtnews
